Ondine reports strong research findings from Canadian hospitals

Ondine Biomedical announced ground-breaking research findings from Vancouver General and University of British Columbia (UBC) Hospitals in British Columbia, Canada, on Monday, after they implemented a universal pre-surgical nasal photodisinfection and chlorhexidine gluconate (CHG) wipes protocol.

The AIM-traded firm said the research revealed a 66.5% reduction in surgical site infection (SSI) rates among spine surgery patients.

It said that despite a concerning rise in antimicrobial resistance, the hospitals managed to substantially reduce SSI rates from 7.98% to 2.67%.

Furthermore, it said the pioneering approach yielded substantial cost savings, amounting to $19.9m over an eight-year study period from 2011 to 2019.

The financial benefits translated into a net annual cost saving of $2.49m.

Ondine added that the research underscored the procedure's long-term safety, with no complications or adverse events associated explicitly with administering nasal photodisinfection.

At 1123 BST, shares in Ondine Biomedical were up 13.9% at 11.39p.

Reporting by Josh White for Sharecast.com.